Imua Raises $5M Seed Round to Launch the AWS for Trust 25-02-2025, 06:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

VCI Global To Distribute AI-Based State Of The Art “Socializer Messenger” For Cogia GmbH 20-06-2023, 18:28